Published On : August 2026
Technologies across the medical devices outsourcing and sterile manufacturing market span ethylene oxide, gamma irradiation, electron beam, steam and hydrogen peroxide alongside other advanced methods.
Packaging formats span blister, pouch, tray, vial and ampoule, pre-filled systems and custom formats.
The two are directly connected because sterilization occurs with the product already inside its packaging in most terminal methods.
Packaging must therefore survive the process while allowing it to work, which is a genuine engineering constraint rather than a procurement preference.
Gas-based methods require packaging permeable to the gas, while radiation methods require materials that do not degrade under exposure.
Material compatibility is consequently assessed jointly rather than separately, and changing one frequently forces reassessment of the other.
Product material also constrains method choice, since heat-sensitive or moisture-sensitive products rule out certain approaches.
The sterile barrier system must maintain sterility from processing through to point of use, which can be years later.
Validation covers both the sterilization process and the packaging system, and both must be demonstrated rather than assumed.
Providers are commercially defined by which methods they operate, and few operate all of them.
Partnership arrangements for methods a provider does not operate are normal, which means a customer's product may travel between sites during production.
This page describes processes and formats as market capabilities and does not provide validation or cycle development guidance.
Sterilization is frequently performed by a third party rather than by the contract manufacturer itself, which means product travels between sites during production. That movement introduces logistics, transit validation and scheduling dependencies that customers should understand rather than assume are handled invisibly.
Dose or cycle qualification is product-specific, so a provider's general capability does not establish that a particular product can be processed on its existing arrangements.
Ethylene oxide is a gas-based method used widely across the medical device industry, particularly for products that cannot tolerate heat or radiation.
Its breadth of material compatibility is why it remains so heavily relied upon despite the operational demands it carries.
Processing requires controlled chambers, defined exposure conditions and an aeration period before product can be released.
That aeration requirement extends cycle times considerably relative to radiation methods, which affects throughput and lead time planning.
Packaging must be permeable so the gas can reach the product and subsequently be removed, which constrains material choice.
The method faces sustained regulatory and environmental scrutiny relating to emissions, and this is the most significant uncertainty in the sterilization landscape.
Facility closures or capacity restrictions in this method would affect a substantial proportion of device production, since alternatives are not available for every product.
That systemic exposure is why alternative capacity development appears among this market's identified opportunities and why customers increasingly ask about it.
Emission control technology has advanced, and facilities have invested substantially in abatement.
Capacity is concentrated among specialist providers rather than distributed across contract manufacturers generally.
The regulatory programmes governing these processes are covered among the regulatory programmes governing these processes.
For manufacturers, understanding their exposure to this method across a product portfolio is a genuine risk management exercise.
Capacity concentration in this method creates a genuine single-point exposure for products that cannot use alternatives. Manufacturers increasingly map which of their products depend on it and whether a second qualified route exists, which is a resilience exercise rather than a procurement one.
Residual testing forms part of release for products processed this way, adding a step and a duration between processing and availability that radiation methods do not require. Manufacturers modelling supply lead times should account for that interval rather than treating sterilization as an instantaneous stage in the production plan.
Gamma irradiation uses a radioactive source to sterilise product, and it penetrates well through packaging and dense product.
Its penetration is its principal advantage, allowing full pallets to be processed rather than individual units.
No aeration is required, so cycle times are shorter than gas-based methods and throughput is correspondingly higher.
Material degradation is the constraint, since some polymers change properties under radiation exposure in ways that affect product performance.
Compatibility must therefore be established for each material and dose combination, which is part of product development rather than a production step.
Source supply and facility licensing are structural considerations, since the radioactive source requires periodic replenishment and tightly regulated handling.
Electron beam uses accelerated electrons rather than a radioactive source, which avoids the source supply question entirely.
Penetration is lower than gamma, which limits it to less dense product and packaging configurations.
Dose rates are much higher, so exposure times are very short, which can reduce material degradation relative to gamma at equivalent dose.
Facilities are electrically powered and can be switched off, which simplifies licensing and operational management considerably.
Both methods have gained attention as alternatives to ethylene oxide, though neither substitutes for it across all products.
Capacity for both is concentrated among specialist sterilization providers rather than held by contract manufacturers themselves.
X-ray sterilization has emerged as a further radiation option combining gamma-like penetration with an electrically generated source. Adoption remains at an earlier stage than the established methods, but interest has grown alongside the wider search for alternatives to gas-based processing.
Facility location matters more for radiation methods than for gas processing, since product must travel to fixed installations that cannot be replicated cheaply. Transport time and cost therefore enter the total cost calculation in a way that on-site processing would avoid, and customers comparing methods should include that logistics element rather than comparing processing cost alone.
Steam sterilization uses saturated steam under pressure and is the most established and lowest-cost method available.
Its economics are excellent, which makes it the default wherever product materials permit it.
The constraint is that many device materials cannot tolerate the temperature and moisture involved, which rules the method out for a large share of modern products.
Polymer components and electronics in particular are frequently incompatible, and these feature heavily in contemporary device design.
Packaging must allow steam penetration while maintaining the sterile barrier afterwards, which is well-established practice.
The method is used extensively in healthcare settings for reusable instruments, which is a different application from contract manufacturing of single-use product.
Hydrogen peroxide methods use vapour or plasma at low temperature, suiting heat-sensitive products that cannot tolerate steam.
Cycle times are short and no toxic residue remains, which simplifies release relative to ethylene oxide.
Penetration is more limited, which constrains packaging configuration and product geometry.
Chamber capacity is generally smaller than radiation facilities, which affects throughput for high-volume products.
Other advanced methods continue to develop, and interest in alternatives has increased with the scrutiny facing ethylene oxide.
For manufacturers, method selection is settled during development rather than at production, since it constrains materials and packaging from the outset.
Method selection constrains material choice from the earliest design stage, which means changing method late in development typically requires revisiting the product itself. Manufacturers who defer the decision frequently discover their material choices have already made it for them.
Blister packaging seals product between a formed cavity and a lidding material, and it is widely used for smaller devices.
It offers product visibility and controlled presentation at opening, both of which matter in clinical use.
Pouch packaging uses flexible materials sealed around the product, and it is the most economical format for many products.
Material selection governs sterilization compatibility, and permeable materials are used where gas methods apply.
Tray packaging holds product in a formed tray with a sealed lid, suiting larger devices and multi-component kits.
Trays present contents in an organised arrangement, which matters for procedure packs where sequence and accessibility are practical considerations.
Vial and ampoule packaging applies to liquid products and drug delivery applications, drawing on pharmaceutical rather than device packaging practice.
Pre-filled systems combine container and delivery device, and they are among the fastest-growing formats alongside drug delivery device growth.
They require both filling and device assembly capability, which is exactly the dual competence that makes combination product providers distinctive.
Custom formats address products that standard configurations cannot accommodate, and they require tooling investment that volume must justify.
The customers commissioning this capacity are covered among the customers commissioning this capacity.
Across all formats, packaging validation is part of the product's compliance record rather than a separate exercise.
Shelf life claims depend on packaging performance over time and are established through stability and ageing studies rather than asserted. Providers offering packaging development generally support that work, and it forms part of the evidence a manufacturer's documentation must carry.
Packaging tooling represents a capital commitment that must be recovered across programme volume, and formats requiring bespoke tooling carry a threshold below which they are uneconomic. Customers with modest volumes therefore find standard formats considerably more accessible than custom ones, regardless of what the product might ideally use.
Ethylene oxide is a gas-based method used widely for products that cannot tolerate heat or radiation. It requires controlled chambers and an aeration period before release, and it faces sustained regulatory and environmental scrutiny over emissions.
Gamma irradiation uses a radioactive source to sterilise product, penetrating well through packaging so full pallets can be processed. No aeration is required, though some polymers degrade under exposure.
A sterile barrier system is the packaging that maintains sterility from processing through to point of use, which can be years later. It is validated as part of the product's compliance record rather than treated as a wrapper.
Terminal sterilization occurs with product already inside its packaging, so packaging must survive the process while allowing it to work. Gas methods need permeable materials; radiation methods need materials that do not degrade under exposure.